ERBB2 and breast carcinoma: Additionally, ablation of RICTOR/mTORC2 signaling subsequent RICTOR knockdown or treatment with mTORC1/2 dual kinase reduced Akt-mediated tumor cell survival and promoted lapatinib-mediated cell killing in HER2+ breast cancer cells, a dual HER2/EGFR tyrosine kinase inhibitor (41).